Medtronic Reports Strong 6.6% Organic Revenue Growth in Q4
Summary
Medtronic reported a solid 6.6% organic revenue increase for its fourth quarter. This positive operational performance follows a period of new product approvals and an acquisition, but also a recent downward revision of fiscal year 2026 EPS guidance. The strong organic growth is a key indicator of the company's core business health and could provide support for the stock, which is currently trading near its 52-week low.
At the time of this announcement, MDT was trading at $74.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $94.7B. The 52-week trading range was $73.31 to $106.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.